Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gossamer Bio Inc
(NQ:
GOSS
)
0.8060
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gossamer Bio Inc
< Previous
1
2
Next >
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
March 12, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 05, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
December 13, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
December 05, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
November 29, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
October 03, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
September 07, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
July 24, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces $212 Million Private Placement Financing
July 20, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
May 18, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
March 17, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
December 06, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces $120 Million Private Placement Financing
July 13, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
June 09, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
April 25, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
February 28, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
November 02, 2021
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
October 11, 2021
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
October 07, 2021
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
September 21, 2021
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021
From
Gossamer Bio, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.